【心泰医疗(02291.HK)拟10.88亿元收购上海民为生物技术54.2384%股权】智通财经APP讯，心泰医疗(02291.HK)发布公告，于2026年8月21日，公司、卖方(乐普(北京)医疗器械股份有限公司)及上海民为生物技术有限公司(目标公司)订立股份转让协议，据此，公司有条件同意收购，且卖方有条件同意出售目标公司合共54.2384%股权，代价为现金人民币10.88亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.